Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editing

Sandra Wimberger, Nina Akrap, Mike Firth, Johan Brengdahl, Susanna Engberg, Marie K. Schwinn, Michael R. Slater, Anders Lundin, Pei-Pei Hsieh, Songyuan Li, Silvia Cerboni, Jonathan Sumner, Burcu Bestas, Bastian Schiffthaler, Björn Magnusson, Silvio Di Castro, Preeti Iyer, Mohammad Bohlooly‐Y, Thomas Machleidt, Steve Rees, Ola Engkvist, Tyrell Norris, Elaine Cadogan, Josep V. Forment, Saša Šviković, Pınar Akçakaya, Amir Taheri‐Ghahfarokhi, Marcello MarescabioRxiv 2022 · DOI

TL;DR

This paper introduces a novel two-drug combination therapy, "2iHDR," that significantly enhances the precision and efficiency of CRISPR-Cas9 genome editing. By simultaneously inhibiting DNA-PK and Polϴ, key enzymes involved in DNA repair, the researchers achieve up to 80% precise gene integration while drastically reducing unwanted mutations and off-target edits, paving the way for more reliable gene therapies.

What Problem Does This Paper Address?

CRISPR-Cas9 gene editing holds immense promise for treating genetic diseases, but its clinical application is hampered by two major limitations: low efficiency of precise DNA integration and the generation of unwanted mutations. These issues stem from the cell's natural DNA repair mechanisms, primarily Non-Homologous End Joining (NHEJ) and Microhomology-Mediated End Joining (MMEJ), which often lead to insertions and deletions (InDels) instead of the desired Homology-Directed Repair (HDR) for precise edits. This paper aims to overcome these limitations by developing a strategy to bias DNA repair towards HDR and minimize error-prone repair pathways.

Methods

The researchers employed a multi-pronged approach:

  • High-Throughput Screening (HTS): They screened a library of over 20,000 small molecules using a "Traffic Light Reporter" (TLR) system in HEK293 cells. This system quantifies DNA repair outcomes by measuring the restoration of eGFP (indicating HDR) or the activation of DsRed (indicating NHEJ) after a Cas9-induced double-strand break.
  • Knock-In Sequencing (KI-Seq): A novel NGS-based pipeline was developed to analyze DNA repair outcomes at Cas9-induced double-strand breaks. KI-Seq assigns InDel profiles to specific repair pathways (NHEJ, MMEJ, HDR-KI, NHEJ-KI, etc.), providing a detailed understanding of editing events.
  • Pharmacological Inhibition: Based on HTS results, they identified and tested DNA-PK inhibitors (like AZD7648) and Polϴ inhibitors (like PolQi1 and PolQi2).
  • Cell Line and Primary Cell Models: Experiments were conducted across various cell lines (HEK293T, Jurkat, HepG2) and primary cells (human CD4+ T cells, hepatocytes, iPSCs) to assess the broad applicability of their findings.
  • Various Donor Templates: The study utilized different types of DNA donor templates (ssDNA, dsDNA) and integration strategies to evaluate the effectiveness of their approach.
  • Advanced Sequencing Techniques: ddPCR and long-read sequencing were used to analyze large deletions, translocations, and off-target edits.

Datasets

  • Screening Library: A library of 20,548 small molecules was used for the high-throughput screen.
  • Genomic DNA from Edited Cells: DNA was extracted from various cell lines and primary cells after CRISPR-Cas9 editing experiments for analysis.
  • Publicly Available Data: Next-generation sequencing data is available in the NCBI Sequence Read Archive database (SRA) under BioProject accession code PRJNA907774.

Key Insights and Ideas

  • DNA-PK Inhibition is Key for HDR: The screening identified DNA-dependent protein kinase (DNA-PK) inhibitors as potent enhancers of HDR and reducers of NHEJ. This suggests a critical role for DNA-PK in directing repair pathway choice.
  • MMEJ Inhibition Further Boosts Precision: While DNA-PK inhibition improved HDR, MMEJ-mediated deletions persisted. Inhibiting DNA Polymerase Theta (Polϴ), a key enzyme in MMEJ, further refined the editing outcome.
  • The Power of Combination (2iHDR): The simultaneous inhibition of DNA-PK and Polϴ (dubbed "2iHDR") proved to be a synergistic strategy, dramatically increasing precise integration efficiency and nearly eliminating InDels.
  • Broad Applicability: The 2iHDR strategy demonstrated effectiveness across a wide range of cell types, including primary cells, and with different donor templates and genomic loci.
  • Reduced Off-Target Effects: Beyond improving on-target editing, 2iHDR also significantly reduced Cas9-associated off-target mutations and translocations, enhancing the safety profile of genome editing.

Key Results

  • Up to 80% Precise Integration: The 2iHDR treatment achieved templated insertion efficiencies of up to 80% in some cases.
  • Near-Elimination of InDels: The combination therapy resulted in nearly no formation of undesired Insertion-Deletions (InDels).
  • Significant HDR Enhancement: AZD7648 (a DNA-PK inhibitor) treatment increased HDR-mediated knock-in efficiencies by up to 12.6-fold in primary human CD4+ T cells.
  • Reduced NHEJ and MMEJ: 2iHDR treatment consistently reduced NHEJ-dependent InDels by up to 13.7-fold and also decreased large deletions associated with MMEJ.
  • Improved Integration in Primary Cells: In primary human CD4+ T cells, 2iHDR treatment showed a 3.5- to 8.6-fold increase in editing efficiency compared to untreated controls.
  • Reduced Off-Target Mutations: The study demonstrated a significant decrease in off-target editing when using 2iHDR.

Limitations and Future Work

  • Shortcomings of KI-Seq: The authors acknowledge that KI-Seq's reliance on small amplicons limits its ability to investigate complex DNA rearrangements. Future work could involve integrating ddPCR and long-read sequencing to address this.
  • Uncharacterized Side Effects: While 2iHDR showed promising results, the authors note that uncharacterized, undesirable side effects of simultaneous NHEJ/MMEJ inhibition cannot be entirely excluded. Further studies investigating the genome-wide impact of this inhibition on spontaneously occurring DSBs are needed.
  • Broad Applicability and Clinical Translation: The study highlights the broad applicability of 2iHDR across various cell types and donor templates, suggesting its potential for accelerating CRISPR-mediated KI for both research and clinical applications. The authors anticipate that this strategy will significantly improve performance over existing methods.

Summary updated

Abstract

ABSTRACT Genome editing tools, especially CRISPR/Cas9-based strategies, have transformed biomedical research and opened opportunities for developing curative treatments for genetic diseases. Despite rapid progress, low efficiency of targeted DNA integration and generation of undesired mutations represent major limitations for genome editing applications. Both issues arise from the interplay between the main DNA Double-Strand Break (DSB) repair pathways, Homology-Directed Repair (HDR), Non-Homologous End Joining (NHEJ), and Microhomology-Mediated End Joining (MMEJ). To improve efficiencies of targeted CRISPR-Cas9 genome editing, we screened a large compound library. This led to the discovery of AZD7648, a DNA-dependent protein kinase (DNA-PK) inhibitor and potent enhancer of CRISPR-Cas9-mediated integration. We demonstrated that AZD7648 increased HDR and decreased mutagenic NHEJ repair, thus resulting in improved performance of precise gene editing. Furthermore, we observed additional improvement of integration efficiency by impairing MMEJ repair through DNA polymerase ⊖ (Pol⊖) inhibition. Combined treatment with AZD7648 and Pol⊖ inhibitors (which we named 2iHDR) substantially increased precision of templated insertions, with efficiencies of up to 80%, and nearly no formation of undesired Insertion-Deletions (InDels). Importantly, 2iHDR also decreased Cas9-associated off-target activity, dramatically improving the performance and fidelity of CRISPR-Cas9 gene editing.
BibTeX
@misc{wimberger2022simultaneous,
  author = {Sandra Wimberger and Nina Akrap and Mike Firth and Johan Brengdahl and Susanna Engberg and Marie K. Schwinn and Michael R. Slater and Anders Lundin and Pei-Pei Hsieh and Songyuan Li and Silvia Cerboni and Jonathan Sumner and Burcu Bestas and Bastian Schiffthaler and Björn Magnusson and Silvio Di Castro and Preeti Iyer and Mohammad Bohlooly‐Y and Thomas Machleidt and Steve Rees and Ola Engkvist and Tyrell Norris and Elaine Cadogan and Josep V. Forment and Saša Šviković and Pınar Akçakaya and Amir Taheri‐Ghahfarokhi and Marcello Maresca},
  title = {{Simultaneous inhibition of DNA-PK and Polϴ improves integration efficiency and precision of genome editing}},
  year = {2022},
  doi = {10.1101/2022.12.15.520396},
  howpublished = {bioRxiv},
}
Figure